insitro

What it is

insitro is an AI-first drug-discovery company founded in 2018 by Daphne Koller. Koller previously served as VP for Computation at Calico and co-founded Coursera; her academic background is in Bayesian machine learning.

Approach

insitro builds drug-discovery pipelines by combining:

• High-throughput cellular perturbation experiments at scale.
• Multi-omic measurements (transcriptomics, proteomics, imaging).
• Patient-derived iPSCs as disease-relevant cellular models.
• Machine-learning models to predict drug effects from cellular data.

Programmes

• Metabolic disease (NASH, diabetes complications) — partnership with Gilead.
• Genetically defined neurological disease — partnership with Bristol Myers Squibb.
• Pipeline includes aging-relevant indications via metabolic disease and neurodegeneration.

Why it’s in this reference

insitro represents the "patient-derived iPSC + multi-omic + ML" wave of drug discovery that’s influential beyond aging per se. Koller’s ex-Calico provenance and the company’s metabolic / neurological focus make many programmes aging-adjacent.

Related entries

Calico, Insilico Medicine, Recursion, Spring Discovery.